Bioretec Q4'25: Commercialization groundwork in progress

Bioretec has been rebuilding its commercial foundation during 2025 and is seeking to restore damaged investor confidence. To finance its growth strategy, the company announced it is considering a 15 MEUR share issue. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.

Topics:

00:00 Introduction

00:15 Bioretec’s year 2025

00:45 Main reasons for stalled growth

02:21 The commercial progress of RemeOs

03:26 Situation in China

04:30 Chances in go-to-market strategy

05:22 Most important things to achieve in the US this year

06:40 Outlook for broadening the portfolio and expanding indications

07:47 Situation in Europe

08:51 Finnish hospitals

09:28 Partnership possibilities

10:38 KPI reporting

12:59 Plans regarding funding